ihealth

CBD: A Potential Ally To Strengthen The Immune System

More and more scientific studies are being conducted worldwide to evaluate the benefits of CBD in the treatment of certain diseases. It seems that cannabinoids are beneficial in regulating the immune system.

So can CBD boost our immunity to help us ward off viruses and germs? Let's take a closer look.

The role of the immune system


The human body is exposed to a multitude of diseases, viruses, infections and bacteria every day. The immune system is actually a collection of cells, tissues and organs whose role is to defend the body against these bacteria, viruses and other agents that can threaten health.

When invaded by a foreign organism or molecules, the immune system reacts very quickly to keep these invaders at bay. In addition to protecting us from external threats, the immune system is also responsible for detecting and eliminating cells that are not functioning properly (such as tumours).

The main players in our immune defence are the white blood cells, which eliminate antigens. Most importantly, they develop a memory so that our body reacts more effectively and quickly when it detects a new invasion.

Several recent studies have highlighted the effects of CBD on our immune system.

CBD: a reliable product to stimulate and strengthen the immune system


Cannabidiol is a natural substance that helps to strengthen the immune system, regardless of age or the health problems an individual faces.

CBD has the ability to boost white blood cell production and decrease inflammation by preventing the action and release of cytokines that can cause dangerous, even fatal, failures.

Many studies also suggest that CBD can help boost immunity and protect the immune system through its anti-stress action. CBD has a beneficial effect on stress and anxiety which when prolonged, can lead to a decline in the immune process due to the modulation of blood flow to the brain. Regular intake of cannabidiol ensures the development of a healthier immune response to various sources of stress. It acts on the activation of serotonin 5-HT1A receptors, a molecule that regulates behaviour and mood among other things.

CBD and the immune system: the scientific evidence


In the absence of scientific studies confirming beyond doubt the benefits of CBD on the immune system, opinions differ among scientists who, for the most part, do not venture any definitive conclusions on this subject.

Some researchers, however, do not hesitate to recognise the immunosuppressive and immunomodulatory character of CBD (which means that it can sort out and destroy the bad cells and strengthen the good ones) and consequently its capacity to regulate the immune system.

For several years now, they have noted the therapeutic effects of the product due to its anti-inflammatory action (especially on the central nervous system). CBD, particularly in the form of oil, is increasingly being used in the treatment of certain autoimmune diseases because it helps to strengthen weakened immune defences and prevent infections.

In addition, a number of research studies on the effects of CBD on cancer patients whose immune system no longer plays a full role have demonstrated the ability of these patients to fight the disease thanks to CBD. CBD has even been shown to limit the progression of certain tumours.

What does it feel like to take CBD?


This question, what does CBD feel like, comes into the mind of most people. The answer is simple, Cannabidiol makes you feel relaxed and calm, while at the same time it works to relieve pain caused by a specific pathology. CBD improves mood and makes you feel better if you are depressed and discouraged and it also inhibits nausea and vomiting.

Users of CBD products say:

If you are feeling pain, after taking CBD you won't feel it anymore.

If you are feeling depressed, after taking CBD you will feel emotionally strong and balanced.

If you can't sleep because you are overexcited, you will feel rested after a good night's sleep, induced by CBD.

If you feel nauseous, after taking CBD you will feel good and nausea-free.

It is true that not all cases or all pathologies are positively affected by cannabidiol, but many of them are, and since it is a compound that generates neither addiction nor dependence, and has minimal and very mild adverse effects on our organism, it makes itself a great alternative to many medications, which on the contrary do cause more serious health problems.
Comment
Suggested
Recent
Cards you may also be interested in
The Importance of Bioprocess Containers - Research News
The growth of single-use technologies can be attributed to the growing need for better, cheaper, and faster biologics production. Active development of individualized biologics and personalized medicines, including patient-specific cellular gene therapies and therapeutic vaccines, demands high sterility and is therefore manufactured using single-use equipment and consumables.   In recent years, more biologics having higher potency that require smaller production volumes, advancements in biosimilars targeting smaller markets, and ongoing improvements in production yields and efficiencies that create production operations at much smaller scales have increased the use of single-use technologies such as single-use bioprocess containers/bags as they are best suited for small volume productions. However, single-use technologies are now slowly moving towards clinical production and commercial operations. In 2020, the US FDA approved 53 new medicines and therapeutic biologics (Source: US FDA). Growth in the biologics market is mainly driven by monoclonal antibodies and human insulin, which are among the leading contributors to the bioprocess containers market. Additionally, the Centre for Biologics Evaluation and Research’s (CBER) (2021-25) strategic plan involves various schemes for boosting the growth of the biologics market.  Compared to traditional bio-manufacturing technologies, single-use systems (SUS) have many advantages, such as reduced requirements for process validation and higher manufacturing flexibility, which ultimately results in higher operating efficiency and reduced manufacturing costs.  Despite these advantages, there is a possibility that the plastic materials used for SUS may leach organic compounds or inorganic substances into the processing fluid or the final drug product, which remains a major concern. Such an undesired change could eventually compromise bioprocessing and might significantly impact the safety, quality, and purity of the drug product.   For More Information Download PDF Brochure @ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=107645832 According to a survey conducted by BioPlan Associates in 2018, 73.3% of respondents agreed that leachables and extractables are major concerns that may limit the use of bioprocessing in the near future. As single-use assembly products are made of processed plastic materials, they often face the problem of contamination from the container due to leachables.  The patent expiry of blockbuster drugs has resulted in increased RD spending by pharmaceutical and biotechnology companies. Patent expiry of biologics leads to increasing RD of biologics and shifts biologics from the pipeline to commercial production. As the development and manufacturing costs of biologics are very high, companies are now gradually focusing on techniques that are more economical than traditional biomanufacturing methods.   Most single-use assemblies are made of multiple materials or layers, including polyethylene, polypropylene, ethylene vinyl alcohol, or nylon. Such products require extensive efforts to separate components into homogeneous components. As a result, most single-use assemblies and their components are not suited for recycling. This leads to the generation of large volumes of solid waste; its disposal is a challenging prospect for biopharmaceutical companies.  Recent Developments In June 2021, Avantor, Inc. (US) acquired RIM Bio, a leading China-based manufacturer of single-use bioprocess bags and assemblies for biopharmaceutical manufacturing applications. This acquisition helped the company expand its bioproduction footprint in China. In April 2021, Sartorius Stedim Biotech (France) opened a new Customer Interaction Center (CIC) in Beijing, China, to expand its presence in China and to meet the high demand from the growing biopharmaceuticals market. In March 2021, Merck KGaA (Germany) invested ~USD 30 million (EUR 25 million) to add a single-use assembly production unit at its Life Science Center in Molsheim, France. With this expansion, the company is accelerating its European expansion plans for single-use technology, which is used for the production of COVID-19 vaccines and other lifesaving therapies.  Key Market Players The bioprocess containers market is dominated by a few globally established players such as Sartorius Stedim Biotech (France), Thermo Fisher Scientific (US), Danaher Corporation (US), and Merck Millipore (Germany)
(no title)
ラブドールをトラックの助手席に座らせて運ばせる客 そのうえ、新藤さんは緊急事態宣言下の今年春ごろ、とんでもない“荷物”の引越しもさせられている。その荷物とは、人間と見紛うほどリアルなラブドールである。 いったいどういう状況でラブドールを運ぶことになったんですか 新藤 その客は古い2DKのマンションに住む30代前半の小柄な男性で、一見すると物静かな印象でした。荷物の量自体は普通のひとり暮らしの男性と同じだったんですが、奥の3畳ほどの部屋だけは、なぜかガラス戸が固く閉まったままでした。そこでガラス戸を開けると、アンティーク風の椅子が真ん中にあり、髪が長くて肌の白い人形がフェミニンな服を着て座っていたんです。ものすごく高品質かつリアルなダッチワイフで、最初は人間の女性に見えました。作業員が集まって「あれはなんだ」「人?」「いや人形じゃないか」とヒソヒソ相談したくらいです。 ─たしかに最近のラブドールのクオリティはすごいと聞きます。 新藤 でも、大変だったのはそこからでした。通常の手順通り、セックス人形にプチプチを巻いて緩衝材の布をかけようとしたら、男性が血相を変えて「何をしているんですか!!」と僕の手をガッとつかんだんです。「梱包して運ぼうとしているんですが」と答えると、男性は「それは違うでしょ。普通は人にそんなことをしない」と真剣な表情で言う。なるほど。男性にとってそのラブドールドールは「人」であり「彼女」なんですね。 https://www.saikodoll.com/ セックス人形と並んで座り新居まで 新藤 そういうことみたいです。それで先輩を交えて男性と相談した結果、トラックの座席にドールを乗せて移動することになりました。通常の作業時は運転手、先輩、僕の3人で座席に乗って移動するんですが、僕は機材を運搬する別の車両に乗り、代わりにセックス人形を助手席に座らせて、ちゃんと人間のようにシートベルトも着用させて運びました。 先輩はめちゃくちゃ恥ずかしかったそうです。新居までの移動時間が1時間あまり。その間、作業着姿のおじさん2人がラブドールと並んで座り、ほかのドライバーからジロジロ見られ続けたわけですから。そういう意味では、この男性は本当に迷惑な客でした。
Protein Engineering : Future, Trends, And Scope
The growth of this market is majorly driven by factors such as the increasing investments in synthetic biology and the growing focus on protein-based drug development by pharmaceutical and biotechnology companies.  The rational protein design segment accounted for the largest share of the market in 2019. The large share of this segment can be attributed to the increasing use and continuous upgrades of bioinformatics platforms and software for protein analysis.  The global market is segmented into four major regions, namely, North America, Europe, the Asia Pacific, and the Rest of the World. In 2019, North America accounted for the largest share of the global market, closely followed by Europe.  Factors such as the presence of well-established CROs, rising R&D expenditure, and the availability of the latest techniques and instruments for drug discovery research are responsible for the large share of the North American market. However, the Asia Pacific market is estimated to grow at the highest CAGR during the forecast period.  Download PDF Brochure @ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=898  Monoclonal antibodies accounted for the largest share of the protein engineering market in 2019, majorly due to the high and growing demand for monoclonal antibodies for the treatment of cancer, neurological diseases, and infectious diseases.  The rational protein design segment accounted for the largest share of the market, majorly due to the increasing use and continuous upgrades of bioinformatics platforms and software for protein analysis.  The protein engineering market is segmented into biopharmaceutical companies, contract research organizations, and academic research institutes. Biopharmaceutical companies use protein engineering products extensively in their drug discovery and development activities as these products help in designing models to develop a broad range of protein-based drugs. As a result, biopharmaceutical companies were the largest end-users in this market in 2019.  The major companies operating in the global protein engineering market include Thermo Fisher Scientific (US), Danaher Corporation (US), Agilent Technologies (US), and Bio-Rad Laboratories (US).  Market Research Developments: In 2019, Creative Biolabs (US) launched the cd25 monoclonal antibody. In 2019, Waters Corporation (US) launched Vanguard FIT Cartridge Technology. In 2019, Agilent Technologies (US) acquired BioTek Instruments (US), which helped the company to expand its expertise in cell analysis and establish its position in the immuno-oncology and immunotherapy markets. In 2019, Merck KGaA signed a license agreement with Amunix Pharmaceuticals, Inc. (US). Under this agreement, Amunix will gain the rights to develop therapeutics using the protease-triggered immune activator (ProTIA) technology platform.
Without Conviction Animal-Cruelty Case To End: Animal Treatment
The growth of the animal treatment market can be attributed to increasing government initiatives, which ensure maximum preventive healthcare for animals. A majority of the developed economies have norms that impel owners to have pet insurance.  By animal type, the horse's segment is expected to register the highest growth rate during the forecast period. Based on animal type, the animal treatment market is segmented into dogs, cats, horses, cattle, pigs, and poultry. The percentage of medical treatment received by horses is predicted to grow by 2024. In several countries, racehorses are considered to be of economic importance. Therefore, it becomes imperative for caretakers to provide maximum preventive as well as long-term veterinary care to equine species, as negligence pertaining to equine species may have an economic impact. On average, over 70-75% of the horses receive maximum preventive healthcare.  By treatment type, the veterinary care segment is expected to register the highest growth rate in the forecast period. Based on treatment type, the animal treatment market is segmented into no medicalization, basic medicalization, and veterinary care. Over the years, the demand for veterinary care services has increased. Veterinary clinics and hospitals in developed as well as developing countries are well-equipped with the necessary equipment for diagnosis and treatment. For instance, Banfield Hospital in the US is one of the most sophisticated hospitals that provides diagnostic tests for animals. North America is the largest market for animal treatment North America is the largest market in terms of the consumption of veterinary products. People are well versed with animal healthcare regulations, and hence high-quality care is provided to animals in this region.  Download PDF Brochure @ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=180479252  However, the animal treatment market has become saturated in the US, as the number of veterinary visits has stabilized. On the contrary, the animal treatment rate in European countries has increased. The increasing standard of living and the growing number of veterinarians providing exceptional medical services to animals are the major factors driving the European animal treatment market. Prominent players in the animal treatment market are Zoetis (US), Merck (US), Boehringer Ingelheim (Germany), Elanco (US), Ceva (France), Phibro Animal Health Corporation (US), Abaxis (US), Virbac SA (France), IDEXX Laboratories, Inc. (US), Neogen Corporation (US), and Heska Corporation (US).